Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy.
Pauline MorignyDoris KalteneckerJulia ZuberJuliano MachadoLisa MehrFoivos-Filippos TsokanosHanna KuziChris D HermannMichael VoelklGerman MonogarovChristoph SpringfeldVictor LaurentBernd EngelmannHelmut FriessInka ZörnigAchim KrügerJeroen KrijgsveldOlga ProkopchukSøren Fisker SchmidtMaria RohmStephan HerzigMauricio Berriel DiazPublished in: Journal of cachexia, sarcopenia and muscle (2021)
Overall, our data show that despite no immediate pathogenic role, at least when targeted as a single entity, PLA2G7 is a consistent marker of CCx in both mice and humans. The early increase in circulating PLA2G7 levels in pre-cachectic mice supports future prospective studies to assess its potential as biomarker for cancer patients.